Health News // 5 hours ago
FDA approves Spravato, first monotherapy nasal spray to treat depression
Jan. 21 (UPI) -- The Food and Drug Administration has approved the first-ever stand-alone nasal spray to treat drug-resistant depression. Johnson & Johnson's Spravato was approved to treat a major depressive disorder, or MDD, in adults.